Carotuximab

Drug Profile

Carotuximab

Alternative Names: Chimeric Antibody (TRC105) to CD105; DE 122; NSC#754227; TRC-105

Latest Information Update: 20 Feb 2017

Price : $50

At a glance

  • Originator Roswell Park Cancer Institute
  • Developer National Cancer Institute (USA); Santen Pharmaceutical; TRACON Pharmaceuticals; University of Alabama at Birmingham
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ENG protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Haemangiosarcoma
  • Phase II Choriocarcinoma; Glioblastoma; Hepatocellular carcinoma; Renal cell carcinoma; Soft tissue sarcoma
  • Phase I/II Breast cancer; Wet age-related macular degeneration
  • Phase I Non-small cell lung cancer
  • Preclinical Acute myeloid leukaemia; Colorectal cancer
  • Discontinued Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer

Most Recent Events

  • 13 Feb 2017 Phase-III clinical trials in Haemangiosarcoma (Late-stage disease; Second-line therapy or greater) in USA (IV) (NCT02979899)
  • 03 Jan 2017 TRACON Pharmaceuticals receives special protocol assessment from the US FDA for a pivotal phase III trial of Carotuximab for Haemangiosarcoma
  • 03 Jan 2017 TRACON Pharmaceuticals plans a phase III trial for Haemangiosarcoma (Late-stage disease; Second-line therapy or greater) in USA and Europe (NCT02979899)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top